Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of cytoreductive surgery in recurrent ovarian cancer.
Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, du Bois A. Harter P, et al. Among authors: du bois a. Expert Rev Anticancer Ther. 2009 Jul;9(7):917-22. doi: 10.1586/era.09.49. Expert Rev Anticancer Ther. 2009. PMID: 19589031 Review.
State-of-the-art first-line treatment of ovarian cancer.
Pfisterer J, Hilpert F, Du Bois A, Meier W, Wagner U. Pfisterer J, et al. Among authors: du bois a. Onkologie. 2003 Oct;26(5):446-50. doi: 10.1159/000072977. Onkologie. 2003. PMID: 14605460 Review.
[Advances in the treatment of ovarian carcinoma].
Pfisterer J, du Bois A, Hilpert F, Wagner U, Meier W. Pfisterer J, et al. Among authors: du bois a. Dtsch Med Wochenschr. 2004 Feb 20;129(8):379-84. doi: 10.1055/s-2004-819897. Dtsch Med Wochenschr. 2004. PMID: 14961446 Review. German. No abstract available.
Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group.
Pfisterer J, du Bois A, Wagner U, Quaas J, Blohmer JU, Wallwiener D, Hilpert F; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Pfisterer J, et al. Among authors: du bois a. Gynecol Oncol. 2004 Mar;92(3):949-56. doi: 10.1016/j.ygyno.2003.12.004. Gynecol Oncol. 2004. PMID: 14984965 Clinical Trial.
[First-line therapy in ovarian cancer].
du Bois A, Pfisterer J. du Bois A, et al. Zentralbl Gynakol. 2004 Oct;126(5):312-4. doi: 10.1055/s-2004-820390. Zentralbl Gynakol. 2004. PMID: 15478049 Review. German.
Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel.
Kommoss F, Kommoss S, Schmidt D, Trunk MJ, Pfisterer J, du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom. Kommoss F, et al. Among authors: du bois a. Gynecol Oncol. 2005 Apr;97(1):195-9. doi: 10.1016/j.ygyno.2004.12.047. Gynecol Oncol. 2005. PMID: 15790458 Clinical Trial.
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.
Hilpert F, Stähle A, Tomé O, Burges A, Rossner D, Späthe K, Heilmann V, Richter B, du Bois A; Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Hilpert F, et al. Among authors: du bois a. Support Care Cancer. 2005 Oct;13(10):797-805. doi: 10.1007/s00520-005-0782-y. Epub 2005 Jul 16. Support Care Cancer. 2005. PMID: 16025262 Clinical Trial.
561 results